Literature DB >> 21056999

Abnormal neurites containing C-terminally truncated alpha-synuclein are present in Alzheimer's disease without conventional Lewy body pathology.

Karen A Lewis1, Yang Su, Olina Jou, Caroline Ritchie, Chan Foong, Linda S Hynan, Charles L White, Philip J Thomas, Kimmo J Hatanpaa.   

Abstract

The pathological hallmark of Parkinson's disease and diffuse Lewy body disease (DLBD) is the aggregation of α-synuclein (α-syn) in the form of Lewy bodies and Lewy neurites. Patients with both Alzheimer's disease (AD) and cortical Lewy pathology represent the Lewy body variant of AD (LBV) and constitute 25% of AD cases. C-terminally truncated forms of α-syn enhance the aggregation of α-syn in vitro. To investigate the presence of C-terminally truncated α-syn in DLBD, AD, and LBV, we generated and validated polyclonal antibodies to truncated α-syn ending at residues 110 (α-syn110) and 119 (α-syn119), two products of 20S proteosome-mediated endoproteolytic cleavage. Double immunofluorescence staining of the cingulate cortex showed that α-syn110 and α-syn140 (full-length) aggregates were not colocalized in LBV. All aggregates containing α-syn140 also contained α-syn119; however, some aggregates contained α-syn119 without α-syn140, suggesting that α-syn119 may stimulate aggregate formation. Immunohistochemistry and image analysis of tissue microarrays of the cingulate cortex from patients with DLBD (n = 27), LBV (n = 27), and AD (n = 19) and age-matched controls (n = 15) revealed that AD is also characterized by frequent abnormal neurites containing α-syn119. Notably, these neurites did not contain α-syn ending at residues 110 or 122-140. The presence of abnormal neurites containing α-syn119 in AD without conventional Lewy pathology suggests that AD and Lewy body disease may be more closely related than previously thought.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21056999      PMCID: PMC2993276          DOI: 10.2353/ajpath.2010.100552

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  39 in total

1.  An improved thioflavine S method for staining neurofibrillary tangles and senile plaques in Alzheimer's disease.

Authors:  R Guntern; C Bouras; P R Hof; P G Vallet
Journal:  Experientia       Date:  1992-01-15

2.  Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro.

Authors:  Wolfgang Hoyer; Dmitry Cherny; Vinod Subramaniam; Thomas M Jovin
Journal:  Biochemistry       Date:  2004-12-28       Impact factor: 3.162

3.  Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice.

Authors:  Masaki Wakamatsu; Aiko Ishii; Shingo Iwata; Junko Sakagami; Yuriko Ukai; Mieko Ono; Daiji Kanbe; Shin-ichi Muramatsu; Kazuto Kobayashi; Takeshi Iwatsubo; Makoto Yoshimoto
Journal:  Neurobiol Aging       Date:  2006-12-14       Impact factor: 4.673

4.  An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde".

Authors:  A Alzheimer; R A Stelzmann; H N Schnitzlein; F R Murtagh
Journal:  Clin Anat       Date:  1995       Impact factor: 2.414

5.  Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.

Authors:  Olga Pletnikova; Neva West; Michael K Lee; Gay L Rudow; Richard L Skolasky; Ted M Dawson; Laura Marsh; Juan C Troncoso
Journal:  Neurobiol Aging       Date:  2004-12-28       Impact factor: 4.673

6.  Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.

Authors:  John P Anderson; Donald E Walker; Jason M Goldstein; Rian de Laat; Kelly Banducci; Russell J Caccavello; Robin Barbour; Jiping Huang; Kristin Kling; Michael Lee; Linnea Diep; Pamela S Keim; Xiaofeng Shen; Tim Chataway; Michael G Schlossmacher; Peter Seubert; Dale Schenk; Sukanto Sinha; Wei Ping Gai; Tamie J Chilcote
Journal:  J Biol Chem       Date:  2006-07-17       Impact factor: 5.157

7.  Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders.

Authors:  George K Tofaris; Pablo Garcia Reitböck; Trevor Humby; Sarah L Lambourne; Mark O'Connell; Bernardino Ghetti; Helen Gossage; Piers C Emson; Lawrence S Wilkinson; Michel Goedert; Maria Grazia Spillantini
Journal:  J Neurosci       Date:  2006-04-12       Impact factor: 6.167

8.  Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells.

Authors:  Kelvin C Luk; Cheng Song; Patrick O'Brien; Anna Stieber; Jonathan R Branch; Kurt R Brunden; John Q Trojanowski; Virginia M-Y Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-05       Impact factor: 11.205

Review 9.  Dementia with Lewy bodies.

Authors:  David Weisman; Ian McKeith
Journal:  Semin Neurol       Date:  2007-02       Impact factor: 3.420

10.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

View more
  16 in total

Review 1.  Cell Biology and Pathophysiology of α-Synuclein.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

2.  Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  J Neurosci       Date:  2012-10-24       Impact factor: 6.167

3.  Hippocampal sclerosis in dementia, epilepsy, and ischemic injury: differential vulnerability of hippocampal subfields.

Authors:  Kimmo J Hatanpaa; Jack M Raisanen; Emily Herndon; Dennis K Burns; Chan Foong; Amyn A Habib; Charles L White
Journal:  J Neuropathol Exp Neurol       Date:  2014-02       Impact factor: 3.685

Review 4.  The emerging role of α-synuclein truncation in aggregation and disease.

Authors:  Zachary A Sorrentino; Benoit I Giasson
Journal:  J Biol Chem       Date:  2020-05-18       Impact factor: 5.157

5.  Icariin reduces α-synuclein over-expression by promoting α-synuclein degradation.

Authors:  Lan Zhang; Cong Shen; Jin Chu; Ying Liu; Yali Li; Li Zhang; Lin Li
Journal:  Age (Dordr)       Date:  2015-07-14

6.  Critical role of truncated α-synuclein and aggregates in Parkinson's disease and incidental Lewy body disease.

Authors:  Kavita Prasad; Thomas G Beach; John Hedreen; Eric K Richfield
Journal:  Brain Pathol       Date:  2012-05-23       Impact factor: 6.508

7.  Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein.

Authors:  Wei Wang; Linh T T Nguyen; Christopher Burlak; Fariba Chegini; Feng Guo; Tim Chataway; Shulin Ju; Oriana S Fisher; David W Miller; Debajyoti Datta; Fang Wu; Chun-Xiang Wu; Anuradha Landeru; James A Wells; Mark R Cookson; Matthew B Boxer; Craig J Thomas; Wei Ping Gai; Dagmar Ringe; Gregory A Petsko; Quyen Q Hoang
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-01       Impact factor: 11.205

8.  C-terminal truncation of α-synuclein promotes amyloid fibril amplification at physiological pH.

Authors:  Ingrid M van der Wateren; Tuomas P J Knowles; Alexander K Buell; Christopher M Dobson; Céline Galvagnion
Journal:  Chem Sci       Date:  2018-05-24       Impact factor: 9.825

9.  RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies.

Authors:  Ilaria Poggiolini; Daniel Erskine; Nishant N Vaikath; Janarthanan Ponraj; Said Mansour; Christopher M Morris; Omar M A El-Agnaf
Journal:  Biomolecules       Date:  2021-05-31

Review 10.  The Synaptic Function of α-Synuclein.

Authors:  Jacqueline Burré
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.